Neurocrine Biosciences posts strong Q3 earnings as INGREZZA drives growth and rare disease expansion gains traction. Find out why NBIX stock is a buy.
Neurocrine Biosciences offers growth and value with strong INGREZZA sales, new drug momentum, and 2027 catalysts. Learn more about NBIX stock here.
Neurocrine Biosciences remains a Buy as strong Q3 results and an underappreciated pipeline lift fair value. Read more on NBIX stock here.
Neurocrine Biosciences stock jumped 13% after Q3 earnings beat estimates and sales guidance rose.
Neurocrine Biosciences (NBIX) just delivered a busy quarter, with better than expected earnings, strong year over year revenue growth, and a higher full year sales outlook for INGREZZA following solid uptake across its key franchises. Despite the strong third quarter, Neurocrine Biosciences shares have eased over the past three months, with a 90 day share price return that declined 12.47%. However, the 3 year total shareholder return of 27.49% and 5 year total shareholder return of 55.34%...
Neurocrine Biosciences stock jumped after strong quarterly earnings. Its gains are fueled by more than just its flagship drug, Ingrezza.
Neurocrine's expanding drug portfolio could drive substantial growth through 2031.
Neurocrine Biosciences reported an expert publication on hyperphagia in Prader Willi syndrome that frames the condition as a complex neurobiological disorder and highlights VYKAT XR as the first FDA approved therapy for this symptom in PWS. The piece reinforces VYKAT XR as a core element of comprehensive, multidisciplinary PWS care, which speaks directly to Neurocrine Biosciences' rare disease positioning and long term treatment responsibility across a patient’s lifespan. We will examine how...
Neurocrine Biosciences shares have pulled back in recent weeks after a multi year climb, which puts a spotlight on whether the current price around US$135 still lines up with what the business is earning. For anyone tracking the stock, the real issue is how that recent market mood squares with the underlying profit engine. Over the past 5 years the stock has returned about 31%, so a lot of the long term optimism about Neurocrine Biosciences is already embedded in the valuation debate. Fresh...
Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.
Neurocrine Biosciences has retreated from its all-time high, creating a buying opportunity for the next phase of growth.
Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.
Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.
Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.